Clinical-stage life sciences company Revelation Biosciences Inc (NASDAQ: REVB) announced on Monday that Gemini priming significantly reduces inflammation in human peripheral blood mononuclear cells (PBMCs) exposed to inflammatory stimuli. The company anticipates similar protective effects in its Phase 1b clinical study in chronic kidney disease (CKD) patients, expected to report top-line data by mid-2025.
In the study, PBMCs primed with Gemini demonstrated a notable reduction in proinflammatory cytokines and an increase in anti-inflammatory cytokines compared to placebo when challenged with high mobility group box protein-1 (HMGB-1) and lipopolysaccharide (LPS). These results suggest Gemini's potential to mitigate inflammation-related damage.
As part of the PRIME Phase 1b trial, Revelation is evaluating PBMC responses in patients with Stage 3 and 4 CKD. Findings will support development programs targeting CKD, acute kidney injury (AKI), and post-surgical infection (PSI). Gemini, an intravenously administered formulation of phosphorylated hexaacyl disaccharide (PHAD®), reprograms the innate immune system to moderate its inflammatory response.
Revelation has conducted multiple preclinical and Phase 1 studies demonstrating Gemini's safety and pharmacodynamic activity, positioning it as a potential treatment to reduce inflammation-related complications in kidney disease and surgical recovery.
Sebela Pharmaceuticals' tegoprazan Phase 3 TRIUMpH studies in GERD achieve positive topline results
BioArctic secures European substance patent for Parkinson's drug candidate exidavnemab
Pharming receives UK NICE recommendation for Joenja to treat APDS in patients aged 12 and older
Tagworks Pharmaceuticals' TGW101 IND application granted FDA clearance for Phase 1 clinical trial
1Cell.Ai launches OncoIncytes multi-modal cancer diagnostic panel
Viatris seeks Japanese approval for Effexor for generalised anxiety disorder
Kelun-Biotech's SKB518 granted IND clearance by US FDA
WuXi Biologics completes PPQ campaign at 15,000L production line in Hangzhou
SparX to present Phase 1 clinical update during AACR 2025
Sol-Gel Technologies sells US rights to EPSOLAY and TWYNEO to Mayne Pharma for USD16m
Clario partners with AWS on advancing clinical data analysis with generative AI
Mezzion Pharmaceuticals welcomes dedicated ICD-10 diagnosis codes for Fontan-associated conditions
TNF Pharmaceuticals showcases isomyosamine's clinical promise at BGS Spring Meeting 2025